Miles C Andrews

Miles C Andrews

UNVERIFIED PROFILE

Are you Miles C Andrews?   Register this Author

Register author
Miles C Andrews

Miles C Andrews

Publications by authors named "Miles C Andrews"

Are you Miles C Andrews?   Register this Author

30Publications

847Reads

32Profile Views

Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy.

Front Immunol 2018 4;9:946. Epub 2018 May 4.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.00946DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945998PMC
July 2019

Immunotherapy resistance: the answers lie ahead - not in front - of us.

J Immunother Cancer 2017 21;5:10. Epub 2017 Feb 21.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit Number 1484, Houston, TX 77030 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0212-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319188PMC
March 2019

The good, the (not so) bad and the ugly of immune homeostasis in melanoma.

Immunol Cell Biol 2018 05 2;96(5):497-506. Epub 2018 Feb 2.

Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imcb.12001DOI Listing
May 2018

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

Cell 2017 Sep 10;170(6):1120-1133.e17. Epub 2017 Aug 10.

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.07.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591072PMC
September 2017

Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.

Australas J Dermatol 2017 Aug 11;58(3):e109-e112. Epub 2016 May 11.

Medical Oncology Unit, Austin Health, Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.12488DOI Listing
August 2017

Hallmarks of response to immune checkpoint blockade.

Br J Cancer 2017 Jun 18;117(1):1-7. Epub 2017 May 18.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.136DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520201PMC
June 2017

Systems analysis identifies miR-29b regulation of invasiveness in melanoma.

Mol Cancer 2016 11 16;15(1):72. Epub 2016 Nov 16.

Department of Medicine, University of Melbourne, Parkville, VIC, 3010, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-016-0554-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112703PMC
November 2016

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.

Clin Cancer Res 2015 Dec 22;21(23):5222-34. Epub 2015 Jul 22.

Medical Oncology, Austin Health, Austin Hospital, Heidelberg, Victoria, Australia. Ludwig Institute for Cancer Research, Austin Branch, Heidelberg, Victoria, Australia. Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0393DOI Listing
December 2015

Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells.

Front Oncol 2014 17;4:367. Epub 2014 Dec 17.

Cancer Immunobiology Laboratory, Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Olivia Newton John Cancer and Wellness Centre , Melbourne, VIC , Australia ; School of Cancer Medicine, La Trobe University , Melbourne, VIC , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269118PMC
January 2015

Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.

Expert Rev Clin Immunol 2014 Aug 17;10(8):1107-23. Epub 2014 Jun 17.

Ludwig Institute for Cancer Research, Melbourne-Austin Branch, Cancer Immuno-biology Laboratory, Heidelberg, VIC 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/1744666X.2014.929943DOI Listing
August 2014

The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.

Oncoimmunology 2014;3(7):e946367. Epub 2014 Jul 3.

Ludwig Institute for Cancer Research; Melbourne-Austin Branch; Cancer Immuno-biology Laboratory ; Heidelberg, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/21624011.2014.946367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292757PMC
July 2014

Evolving role of tumor antigens for future melanoma therapies.

Future Oncol 2014 Jun;10(8):1457-68

Ludwig Institute for Cancer Research Ltd, Olivia Newton-John Cancer & Wellness Centre, Cancer Immunobiology, Heidelberg, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.14.84DOI Listing
June 2014

A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.

Melanoma Res 2014 Apr;24(2):144-9

aLudwig Institute for Cancer Research - Austin Branch, Joint Ludwig-Austin Medical Oncology Unit, Olivia Newton John Cancer and Wellness Centre, Austin Health bEastern Health Clinical School, Monash University, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000036DOI Listing
April 2014

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

J Clin Oncol 2013 Dec 4;31(35):e448-51. Epub 2013 Nov 4.

Joint Ludwig-Austin Oncology Unit, Austin Health, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.4118DOI Listing
December 2013

Antioxidant vitamins and adrenocorticotrophic hormone-induced hypertension in rats.

Clin Exp Hypertens 2007 Oct;29(7):465-78

High Blood Pressure Research Unit, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10641960701615774DOI Listing
October 2007

Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat.

Am J Hypertens 2005 Jul;18(7):910-6

High Blood Pressure Research Unit, John Curtin School of Medical Research, Australian National University, Australian Capital Territory, Canberra, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjhyper.2005.02.017DOI Listing
July 2005

Nitric oxide donation lowers blood pressure in adrenocorticotrophic hormone-induced hypertensive rats.

Clin Exp Hypertens 2004 Aug;26(6):499-509

High Blood Pressure Research Unit, The John Curtin School of Medical Research, The Australian National University, Canberra, Australia.

View Article

Download full-text PDF

Source
August 2004

Adrenocorticotropic hormone, blood pressure, and serum erythropoietin concentrations in the rat.

Am J Hypertens 2004 May;17(5 Pt 1):457-61

High Blood Pressure Research Unit, John Curtin School of Medical Research, Australian National University, GPO Box 334, Canberra, ACT 2601, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjhyper.2004.01.004DOI Listing
May 2004

The nitric oxide system in glucocorticoid-induced hypertension.

J Hypertens 2002 Jun;20(6):1035-43

The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00004872-200206000-00003DOI Listing
June 2002